PAKIANATHAN DEEPIKA

Average Profitability
36.66%
Insider Buys Quantity
5
Insider Buys Sum
$18.99M
Insider Sells Quantity
7
Insider Sells Sum
$1.45M

Insider Activity of PAKIANATHAN DEEPIKA

According to the SEC Form 4 filings, PAKIANATHAN DEEPIKA, being in a position of

  1. director at Karyopharm Therapeutics Inc.,
    оver the last 12 months, has bought 0 shares, and sold 1494914 shares for $1.45M,
    over all time since 2013-11-12, has bought 944746 shares for $18.99M, and sold 1494927 shares for $1.45M.

The largest purchase of all time was on 2013-11-12 and amounted to 625000 shares of Karyopharm Therapeutics Inc. for $10M.

The largest sale of all time was on 2024-06-05 and amounted to 468044 shares of Karyopharm Therapeutics Inc. for $448,480.

Biography of PAKIANATHAN DEEPIKA

No biography is available at this moment.

2024-06-07SaleKaryopharm Therapeutics Inc.
KPTI
director
2,240
0.0018%
$0.95$2,130-11.27%
2024-06-06SaleKaryopharm Therapeutics Inc.
KPTI
director
118,452
0.096%
$0.98$116,415-12.22%
2024-06-05SaleKaryopharm Therapeutics Inc.
KPTI
director
468,044
0.3619%
$0.96$448,480-14.1%
2024-06-04SaleKaryopharm Therapeutics Inc.
KPTI
director
341,040
0.2976%
$0.95$324,704-7.9%
2024-06-03SaleKaryopharm Therapeutics Inc.
KPTI
director
360,744
0.3105%
$1.00$360,997-12.71%
2024-05-31SaleKaryopharm Therapeutics Inc.
KPTI
director
204,394
0.1709%
$0.95$194,992-11.03%
2022-06-08SaleKaryopharm Therapeutics Inc.
KPTI
13
<0.0001%
$6.00$78-33.44%
2015-01-12PurchaseKaryopharm Therapeutics Inc.
KPTI
director
90,908
0.2841%
$33.00$3M-16.15%
2014-05-23PurchaseKaryopharm Therapeutics Inc.
KPTI
director
3,538
0.0119%
$26.45$93,568+27.85%
2014-05-22PurchaseKaryopharm Therapeutics Inc.
KPTI
director
40,000
0.1351%
$26.09$1.04M+29.76%
2014-05-21PurchaseKaryopharm Therapeutics Inc.
KPTI
director
185,300
0.6239%
$26.19$4.85M+28.82%
2013-11-12PurchaseKaryopharm Therapeutics Inc.
KPTI
director
625,000
2.111%
$16.00$10M+113.03%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.